On December 19, 2012 AIMM Therapeutics reported a strategic partnership with Cosmo Pharmaceuticals to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma (Press release, AIMM Therapeutics, DEC 19, 2012, View Source [SID:1234500902]). Under the agreement, Cosmo Pharmaceuticals will formulate novel human monoclonal antibodies generated by AIMM Therapeutics in an extended release form exploiting its proprietary MMX technology. No financial details were disclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jan de Vries, CEO of AIMM Therapeutics, said, "The strong preclinical in vivo data generated by Cosmo using its MMX technology show the tremendous potential of oral antibody delivery for gastrointestinal diseases. We expect that the combination of Cosmo’s MMX technology with AIMM’s antibodies will allow us to build a unique portfolio of products with a compelling competitive advantage in gastrointestinal disease." Mauro Ajani, Chairman and CEO of Cosmo Pharmaceuticals, said, "Access to AIMM’s proprietary high quality antibodies through our partnership will enable us to rapidly advance the oral delivery of diagnostic and therapeutic antibodies into clinical studies.‘’